Regeneron’s Libtayo Surround Program
Regeneron offers the Libtayo Surround program to assist patients while taking Libtayo (Table).
Libtayo Surround Program
This program offers an array of patient support services to help patients throughout their treatment journey, including a Commercial Copay Program, Patient Assistance Program, dedicated Patient Navigators, and a Patient Starter Kit.
Commercial Copay Program
Eligible patients with commercial insurance may pay as little as $0 for Libtayo, which includes any product-specific copay, coinsurance, and insurance deductibles, with a cap of $25,000 annually.
Patient Assistance Program
The Libtayo Surround Patient Assistance Program provides access to Libtayo at no cost to eligible patients.
Once enrolled in Libtayo Surround, patients have access to dedicated Patient Navigators who will answer any questions about resources and support, send reminders about upcoming appointments, send patients a Patient Starter Kit to provide helpful materials for starting treatment with Libtayo, and send emails and direct mail to help educate patients and caregivers about their condition and treatment.
To learn more or to enroll your patient in the Libtayo Surround program, call 877-542-8296 or visit Libtayohcp.com.
TABLE Regeneron/Sanofi Genzyme Oncology Drug
Patient support programs
Libtayo (cemiplimab-rwlc) injection
Treatment of metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC in patients who are not candidates for curative surgery or radiation
Treatment of patients with locally advanced or metastatic basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate
First-line treatment in combination with platinum-based chemotherapy in patients with non–small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations and that is either metastatic or locally advanced where patients are not candidates for surgical resection or definitive chemoradiation; or as first-line single-agent treatment of patients with NSCLC whose tumors have high PD-L1 expression as determined by an FDA-approved test, with no EGFR, ALK, or ROS1 aberrations and that is either metastatic or locally advanced where patients are not candidates for surgical resection or definitive chemoradiation
Patient support program